Abstract:OBJECTIVE:To determine the diagnostic and clinical significance of C4d accumulation in renal allografts followed by acute rejection. METHODS:A total of 158 graft biopsies performed from December 1997 to December 2002 were classified, according to the Banff-97 criteria, into hyperacute rejection (HAR, three cases), acute vascular rejection (AVR, 27), acute cellular rejection (ACR, 24), borderline rejection (BR, 38), acute tubular necrosis (ATN, five), stable graft function (SGF, 30) and baseline kidney (31). Immunohistochemical technique was used to determine the C4d deposition level. RESULTS:The percentages of C4d positive in HAR, AVR, ACR, BR, ATN, SGF and baseline kidney groups were 100% (3/3), 77.8% (21/27), 37.5% (9/24), 23.7% (9/38), 0% (0/5), 3.3% (1/30), 0% (0/31), respectively. In acute rejection patients, the peak serum creatinine (sCr) level in C4d(ptc)-positive group (41 cases) was 334.82 +/- 238.37 micromol/L, with that of C4d(ptc)-negative group (47 cases) being 220.20 +/- 176.94 micromol/L (p < 0.01). After treatment, the trough sCr level in C4d(ptc)-positive group and C4d(ptc)-negative group were 176.87 +/- 111.80 and 121.75 +/- 34.59 micromol/L (p < 0.01), respectively. In each AVR, ACR and BR subgroups, the peak sCr level, the trough sCr level, after 3 or 6 months of AR, the sCr level in C4d(ptc)-positive subgroup was higher than that of C4d(ptc)-negative subgroup. There were more resistance against steroid therapy [65.9% (27/41) vs. 36.2% (17/47), p = 0.005] and a higher rate of graft loss [29.3% (12/41) vs. 6.4% (3/47), p = 0.001] in C4d(ptc)-positive group than those of C4d(ptc)-negative group. In each C4d(ptc)-positive subgroup of AVR, ACR and BR the complete reversion was 57.1, 56 and 66.7%, respectively, it is almost same. CONCLUSION:The C4d deposition level is of great value in diagnosis of acute rejection caused by humoral immune components. It is a significant predictor of graft survival and will be of great help when treating acute rejection.

Pathological Study Progress of C_4d

Pros and Cons for C4d As a Biomarker.

Accurate Visualization of C4d Complement Fragment in Immunohistochemistry by C-Terminal Linear Neoepitope-Specific Antibodies

The diagnostic significance of C4d deposits, as an immunohistochemical proof of complement activation, in kidney glomerular pathologies and kidney transplantation

C4d deposition is associated with immune cells infiltrating in kidney allograft glomerulitis and peritubular capillaritis.

Noninvasive and Quantitative Measurement of C4d Deposition for the Diagnosis of Antibody-Mediated Cardiac Allograft Rejection

Clinical Implication of Complement Split Product C4d in Patients with Antibody-Mediated Chronic Rejection

C4d as a significant predictor for humoral rejection in renal allografts.

Complement C4d as a biomarker for systemic lupus erythematosus and lupus nephritis

COMPARATIVE STUDY FOR THE IMMUNOHISTOCHEMICAL METHODS OF C4D IN RENAL ALLOGRAFT BIOPSIES

Research Progress of Complement Component 3(C3) Gene Polymorphism with Related Diseases

Study for complementarity determining region 3 of T cell receptor beta chain in infectious diseases

Clinical value of complements detection in C3 glomerulopathy

The diagnostic value of immunohistochemical staining of the interstitial vascular C4d complement in membranous nephropathy

Complement C1s as a diagnostic marker and therapeutic target: Progress and propective

Exepression and Significance of C4d in Small Bowel after Transplantation

Systemic Lupus Erythematosus and Hereditary Complement Dificiency

[Complement System Regulation and C3 Glomerulopathy].

The Solvent at Antigen-Binding Site Regulated C3d-CR2 Interactions Through the C-terminal Tail of C3d at Different Ion Strengths: Insights from Molecular Dynamics Simulation.

C3‐dependent effector functions of complement

The molecular mechanism of pH regulating C3d-CR2 interactions: insights from molecular dynamics simulation.